Summary

Eligibility
for people ages up to 29 years (full criteria)
Location
at UC Davis UCLA UCSF
Dates
study started
completion around

Description

Summary

This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib and sorafenib tosylate together with combination chemotherapy may be an effective treatment for acute myeloid leukemia.

Official Title

A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD

Details

Keywords

Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma, Leukemia, Myeloid Leukemia, Leukemia, Myeloid, Acute, Cytarabine, Etoposide, Podophyllotoxin, Daunorubicin, Mitoxantrone, Etoposide phosphate, Bortezomib, Sorafenib, Asparaginase, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Pharmacological Study, Quality-of-Life Assessment, Sorafenib Tosylate

Eligibility

Locations

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
Links
Data Available: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive.
ID
NCT01371981
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 1645 people participating
Last Updated